Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler
Overall, bioequivalence was confirmed of HFA-152a and HFA-134a for BDP 200 μg/actuation, with and without a spacer. Although bioequivalence of the two formulations cannot be formally concluded for BDP 100 μg, the minimal difference suggests the two formulations can be considered therapeutically equivalent.
Authors
- Ilaria Pacchetti
- Luca Viganò (ORCID: https://orcid.org/0000-0002-4108-4832)
- Matteo Martini (ORCID: https://orcid.org/0000-0001-9873-9695)
- K van Leuven
- François Rony
- Gianluigi Poli (ORCID: https://orcid.org/0000-0002-3758-7664)
- Maria Gloria Pittelli (ORCID: https://orcid.org/0000-0003-4851-699X)
- Kusum S. Mathews (ORCID: https://orcid.org/0000-0002-8810-2794)
- Emanuele Calabrò (ORCID: https://orcid.org/0000-0001-5487-7869)
- Cristina Contursi
Institutions
- Chiesi (Italy) (IT)
Publication Details
- Journal
- Pulmonary Pharmacology & Therapeutics
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1016/j.pupt.2025.102356
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chiesi Farmaceutici